The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania ...

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

The ADR's fall snapped a three-day winning streak.

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...